ReviewMolecular biology reports2026
Fluorogenic RNA aptamers in cancer: emerging platforms for molecular imaging, biosensing, and precision oncology.
Review in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fluorogenic RNA aptamers have emerged as powerful molecular tools for cancer imaging, biosensing, and biomarker detection due to their high specificity, low background fluorescence, and genetic encodability. These short RNA molecules activate fluorescence upon binding specific fluorogens, enabling real-time visualization of intracellular targets and dynamic molecular processes in living systems. Recent advances in RNA structural engineering, fluorophore optimization, and biosensor integration have significantly expanded the translational applications of fluorogenic aptamers in oncology. This mini-review summarizes the structural principles, fluorescence activation mechanisms, and cancer-related applications of fluorogenic RNA aptamers and related nucleic acid biosensors. Foundational studies describing the architecture of fluorogenic aptamer families, including Spinach, Broccoli, Mango, Pepper, Squash, and Beetroot, are discussed with emphasis on G-quadruplex-mediated fluorogen stabilization and fluorescence enhancement. Furthermore, recent developments in CRISPR/Cas-assisted fluorogenic biosensors, dual-color RNA imaging systems, fluorogenic DNAzymes, and amplification-driven aptamer platforms are highlighted. Direct applications across multiple malignancies, including brain, breast, colorectal, liver, lung, prostate, and skin cancers, demonstrate the growing utility of these technologies for tumor-associated RNA detection, epigenetic biomarker analysis, molecular imaging, and therapeutic monitoring. In addition, advances in fluorescence brightness, structural stability, and multiplex imaging strategies have improved the sensitivity and adaptability of fluorogenic RNA systems for complex biological environments. Despite current limitations related to RNA stability, intracellular delivery, and tissue penetration, fluorogenic RNA aptamers represent highly promising tools for next-generation precision oncology. Continued integration with nanotechnology, live-cell imaging, artificial intelligence, and molecular diagnostics is expected to enhance further their clinical and translational potential in cancer research and personalized medicine.
Indexed as
Identifiers
42886424What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.